Literature DB >> 11558632

Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma.

Y Ito1, S Higashiyama, T Takeda, Y Yamamoto, K I Wakasa, N Matsuura.   

Abstract

BACKGROUND: Previous studies demonstrated that heparin-binding epidermal growth factor-like growth factor (HB-EGF) contributes to carcinogenesis and carcinoma progression. In this study, we investigated its expression in human pancreatic adenocarcinoma.
METHODS: We immunohistochemically investigated the expression of HB-EGF in 40 cases of pancreatic adenocarcinoma.
RESULTS: HB-EGF was only occasionally and faintly expressed in normal and hyperplastic pancreas duct epithelia. In pancreatic adenocarcinoma, 22 (55.0%) of the 40 cases were classified as positive for HB-EGF. Its expression was more frequently observed in cases with a low Ki-67 labeling index, well differentiated. early stage, small size, without lymph node metastasis and low EGF-R expression.
CONCLUSION: These results suggest that HB-EGF mainly plays a role in early phase of the progression of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558632     DOI: 10.1385/IJGC:29:1:47

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  14 in total

1.  High expression of heparin-binding EGF-like growth factor in rat hepatocarcinogenesis.

Authors:  E Miyoshi; S Higashiyama; T Nakagawa; K Suzuki; M Horimoto; N Hayashi; H Fusamoto; T Kamada; N Taniguchi
Journal:  Int J Cancer       Date:  1996-10-09       Impact factor: 7.396

2.  The cell cycle associated change of the Ki-67 reactive nuclear antigen expression.

Authors:  K Sasaki; T Murakami; M Kawasaki; M Takahashi
Journal:  J Cell Physiol       Date:  1987-12       Impact factor: 6.384

3.  Localization of heparin-binding epidermal growth factor-like growth factor in human gastric mucosa.

Authors:  Y Murayama; J Miyagawa; S Higashiyama; S Kondo; M Yabu; K Isozaki; Y Kayanoki; S Kanayama; Y Shinomura; N Taniguchi
Journal:  Gastroenterology       Date:  1995-10       Impact factor: 22.682

4.  Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein.

Authors:  S Higashiyama; K Lau; G E Besner; J A Abraham; M Klagsbrun
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

5.  The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; U S Joshi; Y C Chen; W Du; D W Smith; P Arlauskas; J D Crissman; V K Vaitkevicius; F H Sarkar
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

6.  Heparin-binding EGF-like growth factor is a potent mitogen for rat hepatocytes.

Authors:  N Ito; S Kawata; S Tamura; S Kiso; H Tsushima; D Damm; J A Abraham; S Higashiyama; N Taniguchi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1994-01-14       Impact factor: 3.575

7.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

8.  Tissue distribution of mRNA for heparin-binding epidermal growth factor.

Authors:  T J Vaughan; J C Pascall; K D Brown
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

9.  Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer.

Authors:  N Harada; S Gansauge; F Gansauge; H Gause; S Shimoyama; T Imaizumi; T Mattfeld; M H Schoenberg; H G Beger
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor.

Authors:  S Higashiyama; R Iwamoto; K Goishi; G Raab; N Taniguchi; M Klagsbrun; E Mekada
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  5 in total

Review 1.  MicroRNAs in pancreatic cancer metabolism.

Authors:  Pankaj K Singh; Randall E Brand; Kamiya Mehla
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

2.  High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF.

Authors:  Andreas-Claudius Hoffmann; Ryutaro Mori; Daniel Vallbohmer; Jan Brabender; Uta Drebber; Stephan E Baldus; Ellen Klein; Mizutomo Azuma; Ralf Metzger; Christina Hoffmann; Arnulf H Hoelscher; Kathleen D Danenberg; Klaus L Prenzel; Peter V Danenberg
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

3.  HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma.

Authors:  Luigia Rao; Donato Giannico; Patrizia Leone; Antonio Giovanni Solimando; Eugenio Maiorano; Concetta Caporusso; Loren Duda; Roberto Tamma; Rosanna Mallamaci; Nicola Susca; Alessio Buonavoglia; Matteo Claudio Da Vià; Domenico Ribatti; Vallì De Re; Angelo Vacca; Vito Racanelli
Journal:  Cancers (Basel)       Date:  2020-01-10       Impact factor: 6.639

4.  Characterization of a Novel Anti-Human HB-EGF Monoclonal Antibody Applicable for Paraffin-Embedded Tissues and Diagnosis of HB-EGF-Related Cancers.

Authors:  Ryo Iwamoto; Mika Takagi; Jun-Ichi Akatsuka; Ken-Ichiro Ono; Yoshiro Kishi; Eisuke Mekada
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2016-03-14

5.  Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.

Authors:  Kathrin Hedegger; Hana Algül; Marina Lesina; Andreas Blutke; Roland M Schmid; Marlon R Schneider; Maik Dahlhoff
Journal:  Mol Oncol       Date:  2020-05-18       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.